- Cephalon posted a loss in 1995 of $33 million, down from the year-earlier loss of $36.1 million. The loss per share was $1.63, compared with $2.13. Revenues advanced 117% to $47 million, resulting mainly from collaborative agreements, particularly with Chiron Corporation.
In the 1995 fourth quarter, the firm recorded revenues up 24.5% to $10.3 million, and a net loss of $11.8 million, compared with $9.9 million in the like, year-earlier quarter. The loss per share was $0.51, compared with $0.54. Operating expenses grew 47.7% in 1995 due to increased R&D activities. R&D expenditure for the year was $74 million, up 43.4%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze